Recurrence of Psoriasis Vulgaris Accompanied by Treatment with C-C Chemokine Receptor Type 4 (CCR4) Antibody (Mogamulizumab) Therapies in a Patient with Adult T cell Leukemia/ Lymphoma: Insight into Autoinflammatory Diseases

• Published in: Internal Medicine Vol. 55; no. 10; pp. 1345 - 1349
• Main Authors: Morichika, Kazuho, Tomoyose, Takeaki, Hanashiro, Taeko, Shimabukuro, Natsuki, Tamaki, Keita, Tedokon, Iori, Nishi, Yukiko, Nakachi, Sawako, Karube, Ken-nosuke, Fukushima, Takuya, Katoh, Takeharu, Ohshima, Koichi, Masuzaki, Hiroaki
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Internal Medicine 01.01.2016
• Subjects: adult T cell leukemia / lymphoma (ATL); Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; autoinflammatory disease; C-C chemokine receptor type 4 (CCR4); Female; Human T-lymphotropic virus; Human T-lymphotropic virus 1; Human T-lymphotropic virus 1 - immunology; Humans; Leukemia-Lymphoma, Adult T-Cell - drug therapy; Leukemia-Lymphoma, Adult T-Cell - therapy; Middle Aged; Psoriasis - chemically induced; psoriasis vulgaris; Recurrence; regulatory T cell (Treg)
• ISSN: 0918-2918; 1349-7235
• DOI: 10.2169/internalmedicine.55.5997

Adult T cell leukemia / lymphoma (ATL) is one of the most aggressive hematological malignancies caused by human T-lymphotropic virus type-I (HTLV-1). Mogamulizumab is a new defucosylated humanized monoclonal antibody agent which targets C-C chemokine receptor type 4 (CCR4) expressed occasionally on the surface of ATL cells. However, adverse events such as drug eruptions have also been highlighted, at least in part, via the dysfunction of regulatory T cells (Tregs). We herein report a pronounced recurrence of systemic psoriasis vulgaris accompanied by the treatment of mogamulizumab in a patient with ATL. Pathological examinations may suggest a mechanistic link between the recurrence of autoinflammatory diseases and anti-CCR4 antibody therapies.